Factors associated with disease progression in patients with atrial fibrillation and heart failure anticoagulated with rivaroxaban
Key Points:
- Identifies clinical, biochemical, and echocardiographic predictors of worsening heart failure and AF progression in anticoagulated patients.
- Assesses the impact of rivaroxaban on stroke prevention, heart failure hospitalization, and overall cardiovascular outcomes.
- Provides insights for clinicians to optimize anticoagulation strategies and individualized management in AF-HF patients.
Description
Factors Associated with Disease Progression in Patients with Atrial Fibrillation and Heart Failure Anticoagulated with Rivaroxaban explores the key determinants influencing clinical outcomes in AF-HF patients receiving rivaroxaban therapy. This study evaluates disease progression, thromboembolic risk, and heart failure deterioration in this high-risk population.
Be the first to review “Factors associated with disease progression in patients with atrial fibrillation and heart failure anticoagulated with rivaroxaban”
Reviews
There are no reviews yet.